Anakinra Versus Placebo for the Treatment of Acute MyocarditIS

Exclusion Criteria

• •Active coronary disease
• •Clinical Suspicion or proven underlying disease: systemic lupus, antiphospholipid antibodies, Lyme disease, trypanosomiase disease, myositis, signs of sarcoidosis, giant cell myocarditis, treated chronic inflammatory disease, tuberculosis, HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV), Hepatitis B virus (HBV) infection,
• •Latex allergy
• •Pregnancy, breastfeeding
• •Contra-indication to ANAKINRA (known hypersensitivity to the active substance or to any of the excipients, neutropenia \< 1,5.10\^9/L)
• •Renal failure, Creatine Clearance (CrCl) \< 30 ml/min (MDRD)
• •Malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study
• •History of malignancy
• •Non Steroidian Anti Inflammatory drug within the past 14 days
• •Anti Tumor Necrosis Factor (TNF) within the past 14 days
• •No affiliation to the French Health Care System "sécurité sociale"
• •Hepatic impairment = Child-Pugh Class C
• •Mechanical ventilation
• •Circulatory assistance